Claims
- 1. A method for treating a staphylococcal infection in a patient, comprising instilling into the patient a therapeutically effective amount of a composition comprising antibodies or fragments thereof that specifically bind to WTA, wherein treatment results in alleviation or blocking of colonization.
- 2. The method of claim 1, wherein the composition comprises polyclonal antibodies that specifically bind to WTA.
- 3. The method of claim 1, wherein the composition comprises a monoclonal antibody that specifically binds to WTA.
- 4. The method of claim 1, wherein the composition comprises a multiplicity of MAbs that specifically bind WTA, wherein the MAbs have non-identical amino acid sequences.
- 5. The method of claim 1, wherein the composition comprises a chimeric antibody that specifically binds to WTA.
- 6. The method of claim 1, wherein the composition comprises a humanized antibody that specifically binds to WTA.
- 7. The method of claim 1, wherein the composition comprises a human antibody that specifically binds to WTA.
- 8. The method of claim 1, further comprising the instillation of at least one anti-staphylococcal drug.
- 9. The method of claim 8, wherein the anti-staphylococcal drug is selected from lysostaphin and nisin.
- 10. The method of claim 1, wherein the staphylococcal infection is selected from a localized infection, a systemic infection, and a contamination of a foreign body.
- 11. The method of claim 1, wherein the antibody fragments are chosen from Fab, Fab′, F(ab′)2, Fv, SFv, and scFv.
- 12. The method of claim 1, wherein the staphylococcal infection is a S. aureus infection.
- 13. A method for treating a staphylococcal infection in a patient, comprising instilling into the patient a therapeutically effective amount of a composition comprising a soluble form of whole WTA or a fragment of WTA, wherein treatment results in alleviation or blocking of colonization.
- 14. The method of claim 13, further comprising the instillation of at least one anti-staphylococcal drug.
- 15. The method of claim 14, wherein the anti-staphylococcal drug is selected from lysostaphin and nisin.
- 16. The method of claim 13, wherein the staphylococcal infection is selected from a localized infection, a systemic infection, and a contamination of a foreign body.
- 17. The method of claim 13, wherein the staphylococcal infection is a S. aureus infection.
- 18. A composition comprising a therapeutically effective amount of antibodies or fragments thereof that specifically bind to WTA, wherein said antibodies or fragments thereof alleviate or block staphylococcal colonization upon administration to a patient.
- 19. The composition of claim 18, wherein the composition comprises polyclonal antibodies that specifically bind to WTA.
- 20. The composition of claim 18, wherein the composition comprises a monoclonal antibody that specifically binds to WTA.
- 21. The composition of claim 18, wherein the composition comprises a multiplicity of MAbs that specifically bind WTA, wherein the MAbs have non-identical amino acid sequences.
- 22. The composition of claim 18, wherein the composition comprises a chimeric antibody that specifically binds to WTA.
- 23. The composition of claim 18, wherein the composition comprises a humanized antibody that specifically binds to WTA.
- 24. The composition of claim 18, wherein the composition comprises a human antibody that specifically binds to WTA.
- 25. The composition of claim 18, wherein the fragment is chosen from Fab, Fab′, F(ab′)2, Fv, SFv, and scFv.
- 26. The composition of claim 18, wherein the colonization results in a staphylococcal infection selected from a localized infection, a systemic infection, and a contamination of a foreign body.
- 27. The composition of claim 18, wherein the staphylococcal colonization results in a S. aureus infection.
- 28. A vaccine comprising:
(a) the composition of claim 18; and (b) a pharmaceutically acceptable carrier.
- 29. The vaccine of claim 28, wherein the colonization results in a staphylococcal infection selected from a localized infection, a systemic infection, and a contamination of a foreign body.
- 30. The vaccine of claim 28, wherein the staphylococcal colonization results in a S. aureus infection.
- 31. A composition comprising a therapeutically effective amount of a soluble form of whole WTA or fragments thereof, wherein said WTA or fragments thereof alleviate or block staphylococcal colonization upon administration to a patient.
- 32. The composition of claim 31, wherein the colonization results in a staphylococcal infection selected from a localized infection, a systemic infection, and a contamination of a foreign body.
- 33. The composition of claim 31, wherein the staphylococcal colonization results in a S. aureus infection.
- 34. A vaccine comprising:
(a) the composition of claim 31; and (b) a pharmaceutically acceptable carrier.
- 35. The vaccine of claim 34, wherein the colonization results in a staphylococcal infection selected from a localized infection, a systemic infection, and a contamination of a foreign body.
- 36. The vaccine of claim 34, wherein the staphylococcal colonization results in a S. aureus infection.
- 37. An isolated constructed S. aureus organism deficient in WTA, wherein the tagO gene is inactivated during construction.
- 38. The isolated S. aureus organism of claim 37, wherein the organism is ΔtagO.
- 39. The method of claim 1, wherein the instillation is chosen from nasal instillation, oral instillation, airway instillation, and systemic instillation.
- 40. The method of claim 1, wherein the patient suffers from at least one of cystic fibrosis, staphylococcal pneumonia, a staphylococcal contamination of a foreign body, a staphylococcal infection, and staphylococcal nasal colonization.
- 41. The method of claim 40, wherein the staphylococcus that causes at least one of cystic fibrosis, staphylococcal pneumonia, a staphylococcal contamination of a foreign body, a staphylococcal infection, and staphylococcal nasal colonization is S. aureus.
- 42. The method of claim 13, wherein the instillation is chosen from nasal instillation, oral instillation, airway instillation, and systemic instillation.
- 43. The method of claim 13, wherein the patient suffers from at least one of cystic fibrosis, staphylococcal pneumonia, a staphylococcal contamination of a foreign body, a staphylococcal infection, and staphylococcal nasal colonization.
- 44. The method of claim 43, wherein the staphylococcus that causes at least one of cystic fibrosis, staphylococcal pneumonia, a staphylococcal contamination of a foreign body, a staphylococcal infection, and staphylococcal nasal colonization is S. aureus.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is based on and claims the benefit of U.S. Provisional Application Ser. No. 60/430,225, filed Dec. 2, 2002. The entire disclosure of this provisional application is relied upon and incorporated by reference herein.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60430225 |
Dec 2002 |
US |